Overexpression and activation of HER2 has previously been associated with chemotherapy resistance in HER2 gene-amplified cancer cells (21–23), and telomere dysfunction has been associated with platinum sensitivity in cancer cells (17). This evidence concerns the gene ERBB2 and cancer.